gms | German Medical Science

61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010
Joint Meeting mit der Brasilianischen Gesellschaft für Neurochirurgie am 20. September 2010

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

21. - 25.09.2010, Mannheim

Progress in neurooncology: The impact of the introduction of fluorescence-guided resection and the Stupp protocol on overall and progression free survival of glioblastoma patients – observations from a single centre

Meeting Abstract

  • Philipp Slotty - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf, Deutschland
  • Birgit Siantidis - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf, Deutschland
  • Matthias Goeppert - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf, Deutschland
  • Hans-Jakob Steiger - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf, Deutschland
  • Michael Sabel - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010. Mannheim, 21.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP1702

DOI: 10.3205/10dgnc173, URN: urn:nbn:de:0183-10dgnc1737

Veröffentlicht: 16. September 2010
Veröffentlicht mit Erratum: 11. Oktober 2010

© 2010 Slotty et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Fluorescence-guided surgery (FGS) and concomitant radiochemotherapy (Stupp protocol) have recently been introduced as treatment options for patients suffering from Glioblastoma multiforme (GBM). As large multicentre trials have demonstrated the efficacy of these options, we were interested in the impact on the overall survival (OAS) and on the progression-free survival (PFS) of patients treated for GBM in our centre.

Methods: Treatment strategies for patients subject to cytoreductive surgery between 2002 and 2007 for newly diagnosed, primary GBM were retrospectively determined. Patients were divided into Group A (FGS-/Stupp-), Group B (FGS+/Stupp-), Group C (FGS-/Stupp+) and Group D (FGS+/Stupp+). Caplan-Meyer analysis on the groups and regression analysis were conducted for age, gender distribution and preoperative KPS.

Results: A total of 169 patients were included (group A=57, B=43, C=16, D=53). The median PFS and OAS between group A and D differed significantly (7.2 vs 10.0 months; p=0.008 and 10.7 vs 19.3 months; p=0.002). The median PFS and OAS for Group B and C were (5.5.vs 8.2 months; p=0.059 and 13.6 vs 16.3 months; p=0.178). Multivariate analysis revealed no significant differences between group A through D regarding age and preoperative KPS.

Conclusions: The introduction of FGS and the Stupp protocol induced an impressive improvement of PFS and OAS of GBM patients in our centre. Despite the limitations of a single centre study, effects were highly significant. In summary, our study suggests that these treatment options should be available in all centres specialized in the care of GBM patients.


Erratum

The name of the second author has been corrected (before: Sianitidis).